サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1794715

肉腫生検の世界市場

Sarcoma Biopsy

出版日
ページ情報
英文 282 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.16円
肉腫生検の世界市場
出版日: 2025年08月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 282 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

肉腫生検の世界市場は2030年までに2億5,580万米ドルに達する見込み

2024年に2億2,950万米ドルと推定される肉腫生検の世界市場は、2030年には2億5,580万米ドルに達し、分析期間2024-2030年のCAGRは1.8%で成長すると予測されます。リユーザブル肉腫生検デバイスは、本レポートで分析したセグメントの1つであり、CAGRは1.4％を記録し、分析期間終了時には1億6,250万米ドルに達すると予測されています。使い捨て肉腫生検機器セグメントの成長率は、分析期間でCAGR 2.6％と推定されます。

米国市場は6,250万米ドルと推定、中国はCAGR 3.6％で成長予測

米国の肉腫生検市場は、2024年に6,250万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに4,760万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは3.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.6％と1.3％と予測されています。欧州では、ドイツがCAGR約0.9%で成長すると予測されています。

世界の肉腫生検市場- 主要動向と促進要因まとめ

肉腫のサブタイプの管理において正確な生検が重要なのはなぜか？

肉腫は、間葉系組織から発生するまれな悪性腫瘍の不均一なグループであり、治療計画や予後評価の指針となる正確な病理組織学的診断が求められます。骨肉腫、脂肪肉腫、平滑筋肉腫、滑膜肉腫など70以上の異なる亜型があり、正確な生検は良性病変と侵攻性悪性腫瘍を鑑別するための基本です。細針吸引（FNA）、コアニードル生検（CNB）、開腹手術による生検が主な方法であり、それぞれ腫瘍の位置、大きさ、疑われる病理学的所見に基づいて選択されます。これらのうち、画像ガイド下CNBは、最小限の罹患率で十分な組織サンプルを採取できるため、初期診断に望ましい方法となっています。

生検手技の選択は、診断成績、病期分類の正確さ、個別化治療の可能性に直接影響します。生検が不適切に行われた場合、特に集学的な検討なしに行われた場合、腫瘍の播種、不正確な悪性度分類、切除断端の損傷につながる可能性があります。現在、肉腫専門センターでは、腫瘍整形外科医および放射線科医の監督下での生検を義務付けており、最適なサンプル採取、軌道計画、および生検後の外科手術の実行可能性を保証しています。多くの肉腫が治療決定に影響を与える明確な遺伝子融合や変異（例えば、EWSR1、SYT-SSX）を有しているため、分子生物学的検査や細胞遺伝学的検査における生検の重要性も増しています。その結果、生検プロセスは精密診断や次世代シーケンサーのワークフローと統合されつつあります。

肉腫生検の精度と有用性を高める技術革新とは？

画像診断と分子診断の技術的進歩は、肉腫生検の実施、解釈、および臨床的意思決定に活用する方法を変革しつつあります。MRIやCTのような高解像度の画像診断装置の普及は、壊死組織や線維化組織を避けながら、生存腫瘍領域をより正確に標的にすることを可能にしています。特に超音波ガイド下CNBは、リアルタイムの可視化と手技の効率化により、表在性肉腫や軟部肉腫に支持されつつあります。深在性腫瘍では、診断能の向上と合併症の最小化のため、CTガイド下または透視下生検がしばしば採用されています。

デジタル病理学とAIによる組織判読の台頭は、診断のスピードと精度を加速しています。これらのプラットフォームは、迅速なデジタルスライド解析、パターン認識、肉腫専門医とのリアルタイムのコンサルテーションを可能にします。さらに、蛍光in situハイブリダイゼーション（FISH）、逆転写ポリメラーゼ連鎖反応（RT-PCR）、次世代シークエンシング（NGS）などの分子アッセイは、がん原性融合、転座、実用的な変異を同定するために、生検検体で実施されるようになってきています。肉腫ではまだ初期段階であるが、リキッドバイオプシーは疾患のモニタリングや微小残存病変の検出のために組織生検を補完する非侵襲的な方法として研究されています。このような技術により、肉腫治療はより個別化されたバイオマーカー主導型へとシフトしつつあります。

肉腫生検実践を形成している臨床環境と地域は？

肉腫の生検は、腫瘍学、病理学、外科学の専門チームを擁する三次紹介センターで主に行われています。これらのセンターは、高精度の画像誘導生検を実施し、包括的な診断プロファイリングのための分子病理学サービスを統合するための設備を備えています。北米と西欧では、集中化された肉腫ネットワークにより、プロトコール化されたワークフローのもとで生検が実施され、診断ミスを最小限に抑え、治療の連携を最大限に高めています。米国、英国、フランス、ドイツ、オランダは重要な拠点であり、腫瘍委員会の中で集学的チームが生検計画を行い、診断戦略と治療方針の整合性を確保しています。

新興国では、生検の実施方法はヘルスケアのインフラや腫瘍学の専門家へのアクセスによって異なります。都市部では画像ガイド下CNBがますます利用できるようになってきているが、地方の病院では診断目的のために外科的切除に頼ることが多く、手技的リスクが増大し、治療が遅れます。しかし、腫瘍科診療を分散化し、画像診断機器に投資する取り組みにより、生検の利用しやすさは徐々に改善されつつあります。生検の利用における地域格差は、患者の意識、ヘルスケア資金、紹介経路によっても形成されます。アジア太平洋市場、特に日本、韓国、インドでは分子診断の統合が進んでおり、ラテンアメリカと中東では国際的ながんネットワークやNGOとの提携による成長が見られます。

肉腫生検世界市場の成長を促す要因とは？

肉腫生検市場の成長は、希少かつ複雑な肉腫の発生率の増加、画像診断の進歩、プレシジョン・オンコロジーの採用の高まりなど、相互に関連するいくつかの要因によってもたらされます。早期かつ正確な診断は効果的な肉腫治療の基礎であり、生検は標的治療や手術計画への入り口としての役割を果たしています。集学的治療と腫瘍管理の一元化が重視されるようになったことで、生検手技が臨床的先見性をもって実施され、より広範な腫瘍学的経路に組み込まれるようになっています。画像診断、生検針のデザイン、分子検査における技術的改良は、診断の歩留まり、患者の安全性、所要時間を向上させています。

がんに対する意識の高まり、ヘルスケアインフラの拡大、肉腫登録の急増も生検サービスの需要を加速しています。生検サンプルの有用性は組織学にとどまらず、ゲノミクス、プロテオミクス、イムノフェノタイピングにまで拡大し、病理検査室や診断機器メーカーに新たな価値の流れを生み出しています。希少がん研究に対する規制当局の支援は、肉腫に焦点を当てた臨床試験への投資の増加とともに、市場の活性化をさらに後押ししています。さらに、放射線科医や病理医を対象とした研修イニシアティブが、十分なリソースのない環境における能力を高めています。これらの動きを総合すると、肉腫診療の進化において診断の要としての生検の役割が強化されつつあります。

セグメント

製品タイプ（再利用型肉腫生検機器、使い捨て型肉腫生検機器）、エンドユーザー（病院エンドユーザー、外来手術センターエンドユーザー、診断センターエンドユーザー）

調査対象企業の例

  • Abbott Laboratories
  • Agilent Technologies Inc.
  • ANGLE plc
  • Argon Medical Devices
  • Becton, Dickinson and Company（BD）
  • Biocept, Inc.
  • Bio-Rad Laboratories, Inc.
  • Boston Scientific Corporation
  • Cardinal Health Inc.
  • Cook Medical Incorporated
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • GRAIL, Inc.
  • Guardant Health
  • Hologic, Inc.
  • Illumina, Inc.
  • Medtronic plc
  • Myriad Genetics, Inc.
  • QIAGEN N.V.
  • Siemens Healthineers
  • Sterylab S.r.l.
  • Thermo Fisher Scientific Inc.
  • UROMED

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37968

Global Sarcoma Biopsy Market to Reach US$255.8 Million by 2030

The global market for Sarcoma Biopsy estimated at US$229.5 Million in the year 2024, is expected to reach US$255.8 Million by 2030, growing at a CAGR of 1.8% over the analysis period 2024-2030. Reusable Sarcoma Biopsy Devices, one of the segments analyzed in the report, is expected to record a 1.4% CAGR and reach US$162.5 Million by the end of the analysis period. Growth in the Disposable Sarcoma Biopsy Devices segment is estimated at 2.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$62.5 Million While China is Forecast to Grow at 3.6% CAGR

The Sarcoma Biopsy market in the U.S. is estimated at US$62.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$47.6 Million by the year 2030 trailing a CAGR of 3.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.6% and 1.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.9% CAGR.

Global Sarcoma Biopsy Market - Key Trends & Drivers Summarized

Why Is Accurate Biopsy Critical in the Management of Sarcoma Subtypes?

Sarcomas, a heterogeneous group of rare malignant tumors arising from mesenchymal tissues, demand precise histopathological diagnosis to guide treatment planning and prognostic assessment. With over 70 distinct subtypes-including osteosarcoma, liposarcoma, leiomyosarcoma, and synovial sarcoma-accurate biopsy is fundamental to differentiating benign lesions from aggressive malignancies. Fine-needle aspiration (FNA), core needle biopsy (CNB), and open surgical biopsies are the primary methods used, each selected based on tumor location, size, and suspected pathology. Among these, image-guided CNB has become the preferred modality for initial diagnosis due to its ability to retrieve sufficient tissue samples with minimal morbidity.

The choice of biopsy technique directly influences diagnostic yield, staging accuracy, and the feasibility of personalized treatment. Biopsies that are improperly performed-particularly without multidisciplinary input-can lead to tumor seeding, inaccurate grading, or compromised resection margins. Specialized sarcoma centers now mandate biopsy under the supervision of oncologic orthopedic surgeons and radiologists to ensure optimal sample collection, trajectory planning, and post-biopsy surgical feasibility. The importance of biopsy in molecular and cytogenetic testing is also increasing, as many sarcomas harbor distinct gene fusions or mutations (e.g., EWSR1, SYT-SSX) that impact therapeutic decisions. As a result, the biopsy process is becoming more integrated with precision diagnostics and next-generation sequencing workflows.

What Technological Innovations Are Advancing the Accuracy and Utility of Sarcoma Biopsies?

Technological advancements in imaging and molecular diagnostics are transforming the way sarcoma biopsies are performed, interpreted, and utilized for clinical decision-making. The widespread use of high-resolution imaging modalities-such as MRI and CT-enables more accurate targeting of viable tumor regions while avoiding necrotic or fibrotic tissue. Ultrasound-guided CNB, in particular, is gaining favor for superficial and soft-tissue sarcomas due to real-time visualization and procedural efficiency. In deep-seated tumors, CT-guided or fluoroscopy-assisted biopsy is often employed to improve diagnostic yield and minimize complications.

The rise of digital pathology and AI-assisted histological interpretation is accelerating the speed and precision of diagnosis. These platforms enable rapid digital slide analysis, pattern recognition, and real-time consultation with sarcoma specialists. Additionally, molecular assays-such as fluorescence in situ hybridization (FISH), reverse transcription polymerase chain reaction (RT-PCR), and next-generation sequencing (NGS)-are increasingly performed on biopsy specimens to identify oncogenic fusions, translocations, and actionable mutations. Liquid biopsy, though still in its early stages for sarcomas, is being explored as a non-invasive complement to tissue biopsy for disease monitoring and minimal residual disease detection. These technological enablers are facilitating a shift toward more individualized and biomarker-driven sarcoma treatment pathways.

Which Clinical Settings and Geographies Are Shaping Sarcoma Biopsy Practices?

Sarcoma biopsies are predominantly conducted in tertiary referral centers with dedicated oncology, pathology, and surgical teams. These centers are equipped to perform high-precision, image-guided biopsies and integrate molecular pathology services for comprehensive diagnostic profiling. In North America and Western Europe, centralized sarcoma networks ensure that biopsies are performed under protocolized workflows, minimizing diagnostic errors and maximizing treatment coordination. The U.S., U.K., France, Germany, and the Netherlands are key hubs where multidisciplinary teams conduct biopsy planning within tumor boards, ensuring alignment between diagnostic strategy and therapeutic trajectory.

In emerging economies, biopsy practices vary based on healthcare infrastructure and access to oncologic expertise. While image-guided CNB is increasingly available in urban centers, rural hospitals often rely on surgical excision for diagnostic purposes, increasing procedural risks and delaying treatment. However, initiatives to decentralize oncology services and invest in diagnostic imaging equipment are gradually improving biopsy accessibility. Regional disparities in biopsy utilization are also shaped by patient awareness, healthcare funding, and referral pathways. Asia-Pacific markets, particularly Japan, South Korea, and India, are making strides in molecular diagnostic integration, while Latin America and the Middle East are seeing growth through partnerships with international cancer networks and NGOs.

What Factors Are Driving Growth in the Global Sarcoma Biopsy Market?

The growth in the sarcoma biopsy market is driven by several interrelated factors, including the increasing incidence of rare and complex sarcomas, advancements in diagnostic imaging, and the rising adoption of precision oncology. Early and accurate diagnosis remains the cornerstone of effective sarcoma treatment, with biopsy serving as the gateway to targeted therapy and surgical planning. The growing emphasis on multidisciplinary care and centralized tumor management is ensuring that biopsy procedures are performed with clinical foresight and integrated into broader oncology pathways. Technological improvements in imaging, biopsy needle design, and molecular testing are improving diagnostic yield, patient safety, and turnaround times.

Rising cancer awareness, expanding healthcare infrastructure, and the proliferation of sarcoma registries are also accelerating demand for biopsy services. Biopsy sample utility has extended beyond histology to encompass genomics, proteomics, and immunophenotyping, creating new value streams for pathology labs and diagnostic device manufacturers. Regulatory support for rare cancer research, along with increased investment in sarcoma-focused clinical trials, is further boosting market activity. Additionally, training initiatives aimed at radiologists and pathologists are building capacity in under-resourced settings. Collectively, these dynamics are reinforcing the role of biopsy as a diagnostic linchpin in the evolving landscape of sarcoma care.

SCOPE OF STUDY:

The report analyzes the Sarcoma Biopsy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Reusable Sarcoma Biopsy Devices, Disposable Sarcoma Biopsy Devices); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Diagnostic Centers End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Abbott Laboratories
  • Agilent Technologies Inc.
  • ANGLE plc
  • Argon Medical Devices
  • Becton, Dickinson and Company (BD)
  • Biocept, Inc.
  • Bio-Rad Laboratories, Inc.
  • Boston Scientific Corporation
  • Cardinal Health Inc.
  • Cook Medical Incorporated
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • GRAIL, Inc.
  • Guardant Health
  • Hologic, Inc.
  • Illumina, Inc.
  • Medtronic plc
  • Myriad Genetics, Inc.
  • QIAGEN N.V.
  • Siemens Healthineers
  • Sterylab S.r.l.
  • Thermo Fisher Scientific Inc.
  • UROMED

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Sarcoma Biopsy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Soft Tissue and Bone Sarcomas Spurs Growth in Biopsy-Based Diagnostics
    • Increased Emphasis on Early and Accurate Diagnosis Strengthens Business Case for Advanced Biopsy Methods
    • Growth in Image-Guided Biopsy Techniques Enhances Precision and Diagnostic Yield in Sarcoma Cases
    • Adoption of Minimally Invasive Biopsy Approaches Expands Patient Comfort and Compliance
    • Expansion of Tumor Genotyping and Molecular Profiling Drives Demand for High-Quality Biopsy Samples
    • Integration of Liquid Biopsy and Circulating Tumor DNA Analysis Expands Non-Invasive Diagnostic Options
    • Clinical Need for Histopathological Subtyping Fuels Demand for Core Needle and Open Biopsies
    • Rising Awareness of Misdiagnosis in Rare Sarcoma Subtypes Propels Demand for Biopsy Re-Evaluation
    • Growth in Multidisciplinary Sarcoma Centers Strengthens Standardization of Biopsy Protocols
    • Advances in Biomarker Discovery and Tissue Analysis Enhance Biopsy-Driven Research
    • Increasing Demand for Biobanked Sarcoma Tissue Expands Role of Biopsy in Translational Medicine
    • Development of AI-Based Histology Interpretation Tools Accelerates Biopsy Result Turnaround
    • Growth in Personalized Oncology and Targeted Therapies Drives Re-Biopsy at Progression or Recurrence
    • Surge in Clinical Trials for Rare Sarcomas Generates Consistent Demand for Diagnostic Tissue Acquisition
    • Integration of Molecular Pathology in Biopsy Analysis Expands Scope Beyond Morphology
    • Digital Workflow and Cloud-Based Pathology Tools Improve Biopsy Sample Sharing Across Institutions
    • Expansion of Multisite Hospital Networks Fuels Centralized Biopsy Services for Sarcoma Diagnosis
    • Collaborations Between Academic Hospitals and Oncology Biotech Firms Enhance Sample Access
    • Regulatory Push for Diagnostic Standardization in Oncology Improves Biopsy Reporting Quality
    • Increased Emphasis on Quality Control and Accreditation of Biopsy Labs Drives Institutional Investment
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Sarcoma Biopsy Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Sarcoma Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Sarcoma Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Sarcoma Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Reusable Sarcoma Biopsy Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Reusable Sarcoma Biopsy Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Reusable Sarcoma Biopsy Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Disposable Sarcoma Biopsy Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Disposable Sarcoma Biopsy Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Disposable Sarcoma Biopsy Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Diagnostic Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Sarcoma Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • JAPAN
    • Sarcoma Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • CHINA
    • Sarcoma Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • EUROPE
    • Sarcoma Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Sarcoma Biopsy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Sarcoma Biopsy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Sarcoma Biopsy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • FRANCE
    • Sarcoma Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • GERMANY
    • Sarcoma Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Sarcoma Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Sarcoma Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Sarcoma Biopsy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Sarcoma Biopsy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Sarcoma Biopsy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Sarcoma Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • INDIA
    • Sarcoma Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Sarcoma Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Sarcoma Biopsy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Sarcoma Biopsy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Sarcoma Biopsy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Sarcoma Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Sarcoma Biopsy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Sarcoma Biopsy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Sarcoma Biopsy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030
  • AFRICA
    • Sarcoma Biopsy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Sarcoma Biopsy by Product Type - Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Sarcoma Biopsy by Product Type - Percentage Breakdown of Value Sales for Reusable Sarcoma Biopsy Devices and Disposable Sarcoma Biopsy Devices for the Years 2014, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Sarcoma Biopsy by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Sarcoma Biopsy by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Diagnostic Centers End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION